Trial of personalised care after treatment – Prostate cancer: A randomised feasibility trial of a nurse-led psycho-educational intervention by Stanciu, Marian Andrei et al.
  
 
P
R
IF
Y
S
G
O
L
 B
A
N
G
O
R
 /
 B
A
N
G
O
R
 U
N
IV
E
R
S
IT
Y
 
 
Trial of personalised care after treatment – Prostate cancer: A randomised
feasibility trial of a nurse-led psycho-educational intervention
Stanciu, Marian Andrei; Morris, Caroline ; Makin, Matt; Watson, Eila; Bulger,
Jenna; Evans, Richard; Hiscock, Julia; Hoare, Zoe; Edwards, Rhiannon Tudor;
Neal, Richard D.; Yeo, Seow Tien; Wilkinson, Clare
European Journal of Cancer Care
DOI:
10.1111/ecc.12966
Published: 31/03/2019
Peer reviewed version
Cyswllt i'r cyhoeddiad / Link to publication
Dyfyniad o'r fersiwn a gyhoeddwyd / Citation for published version (APA):
Stanciu, M. A., Morris, C., Makin, M., Watson, E., Bulger, J., Evans, R., ... Wilkinson, C. (2019).
Trial of personalised care after treatment – Prostate cancer: A randomised feasibility trial of a
nurse-led psycho-educational intervention. European Journal of Cancer Care, 28(2), [e12966].
https://doi.org/10.1111/ecc.12966
Hawliau Cyffredinol / General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or
other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal
requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private
study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to
the work immediately and investigate your claim.
 22. Jun. 2020
For Peer Review
 
 
 
 
 
 
Trial of personalised care after treatment – prostate cancer 
(TOPCAT-P): A randomised feasibility trial of a nurse-led 
psycho-educational intervention 
 
 
Journal: European Journal of Cancer Care 
Manuscript ID Draft 
Manuscript Type: Original Article 
Keywords: 
Prostate cancer, General Practice, Urology, Needs Assessment, Patient 
Care, Nurse Practitioners 
  
 
 
European Journal of Cancer Care
For Peer Review
TOPCAT-P; RCT of nurse-led intervention 
1 
 
Trial of personalised care after treatment – prostate cancer (TOPCAT-P): A randomised 
feasibility trial of a nurse-led psycho-educational intervention  
 
 
 
Abstract 
Objective: The present parallel randomised control trial evaluated the feasibility of a nurse-led 
psycho-educational intervention aimed at improving the self-management of prostate cancer 
survivors.  
Methods: We identified 305 eligible patients from a district general hospital, diagnosed 9-48 months 
previously, who completed radical treatment, or were monitored clinically (ineligible for treatment). 
Ninety-five patients were recruited by blinded selection and randomised to Intervention (N=48) and 
Control (N=47) groups. Participant allocation was revealed to patients and researchers after 
recruitment was completed. For 36 weeks, participants received augmented usual care (Control) or 
augmented usual care and additional nurse support (Intervention) provided in two community 
hospitals and a university clinic, or by telephone.  
Results: Data from 91 participants (Intervention, N=45; Control, N=46) was analysed. All feasibility 
metrics met predefined targets: recruitment rate (31.15%; 95%CI:25.95%-36.35%), attrition rate 
(9.47%; 95%CI:3.58%-15.36%), and outcome measures completion rates (77%-92%). Forty-five 
patients received the intervention, with no adverse events. The Extended Prostate Cancer Index 
Composite can inform the minimum sample size for a future effectiveness trial. The net intervention 
cost was £317 per patient.  
Conclusions: The results supported the feasibility and acceptability of the intervention, suggesting 
that it should be evaluated in a fully-powered trial to assess its effectiveness and cost-effectiveness.  
 
Trial registration: ISRCTN34516019 
 
Funding: Macmillan Cancer Support 
 
Keywords: Prostate Cancer; General Practice; Urology; Needs Assessment; Patient Care; Nurse 
Practitioners 
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Introduction 
In the UK, prostate cancer is more common among men than breast cancer is for women 
(2014 age standardised data), both being the most common cancers for each gender (Smittenaar, 
Petersen, Stewart, & Moitt, 2016). This difference is likely to increase further by 2035, when it is 
predicted that in absolute terms, there will be more new diagnoses of prostate than breast cancer, 
and 66% more prostate cancer patients will be diagnosed each year (c. 77,000) compared to 2014 (c. 
47,000). Survival rates of prostate cancer are also improving and are predicted to continue to do so, 
as a result of earlier diagnosis and treatment, making follow-up care one of the greatest prostate 
cancer-related challenges facing the National Health Service (NHS) in the decades to come 
(Smittenaar et al., 2016).  
The care needs of prostate cancer survivors are often complex and, if unmanaged, can have 
a substantial impact on quality of life. Firstly, in common with other cancers, the diagnosis of 
prostate cancer is linked with a range of psychological symptoms and conditions, such as anxiety, 
depression (Armes et al., 2009; Ream et al., 2008). Secondly, the most common categories of 
treatment (surgery, radiotherapy, hormone therapy, or a combination thereof) can produce physical 
symptoms, such as sexual dysfunction, urinary or bowel incontinence, hot flushes and bone fracture 
(Shahinian et al., 2005). In turn, these physical symptoms then lead to a range of secondary 
psychosocial problems, such as, increased anxiety, loss of identity, shame, social isolation, reduced 
physical activity, depression (Stein, Syrjala, Andrykowski, 2008). Thirdly, a majority of prostate 
cancer patients live with multiple morbidities (e.g., diabetes, cardiovascular disease), which further 
compound their care needs and complicate the management (Crawford et al., 2011; Daskivitch, et 
al., 2013). Moreover, psychosexual symptoms, anxiety and distress affect not only patients, but also 
their families (Harden et al., 2013; Northouse et al., 2007; Segrin et al., 2012), resulting in a high 
level of complex, unmet needs. The range and complexity of subsequent symptoms of prostate 
cancer survivors, together with the large volume of patients being diagnosed and treated are major 
challenges to improving the quality and consistency of post-treatment care. 
 The capacity of the traditional medical-led model of long-term follow-up care for cancer has 
been increasingly regarded as inadequate and unsustainable (Watson et al., 2016; Bulger et al., 
2014). As with other chronic conditions, the long-term management of cancer treatment side-effects 
is increasingly regarded as being best delivered by nurses, with specialist input provided when 
needed (Jefford et al, 2013; Richardson et al., 2008; Skolarus et al., 2009). Nurse-led care has already 
shown to be effective in managing chronic conditions such as diabetes (Renders et al., 2000), 
depression (Gilbody, 2004), and some cancers (Lewis et al., 2009). This is unsurprising, considering 
that the management of multiple chronic conditions is part of the core skills of general practice 
nurses (NMC, 2015), and leading cancer charities have recognised the opportunity to develop the 
nursing role in primary care and have set up educational programmes to prepare Practice Nurses for 
taking an enhanced role in managing cancer as a long-term condition (Macmillan Cancer Support, 
2013). 
Building on recent work of the National Cancer Research Institute (NCRI) in the UK, novel 
and comprehensive holistic needs assessment instruments are available for cancer patients, but they 
have not been tested for prostate cancer. Prostate cancer is a strong litmus test for whether the use 
of such instruments and models of care – promising as they may be - are effective and cost effective 
when scaled-up at healthcare service level. Similar efforts have already shown some promising 
results (Watson et al., 2016), and together with colleagues from Oxford we adapted and integrated 
local third sector models for use in the NHS. In line with Medical Research Council (MRC) guidelines 
for developing complex interventions (Craig et al., 2013), before a fully-powered evaluation of the 
nurse-led holistic care model can be recommended, questions need to be answered about its 
feasibility and acceptability. The present study aimed to: (1) assess the feasibility metrics of the 
intervention (patient recruitment, attrition and response rates), and its acceptability to patients; (2) 
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pilot the intervention delivery, and collect process data, including the number of appointments 
needed to deliver the intervention, the duration of intervention delivery (planning, travel, patient-
contact and administrative time), the range and severity of the symptoms addressed, and the 
support techniques used; (3) investigate the suitability of key clinical and cost effectiveness 
measures for a future fully-powered trial. Progression to a fully-powered trial is predicated on the 
present study meeting the following pre-determined targets: (a) a recruitment rate of at least 25% of 
the clinically eligible patients (invited to the trial); (b) an attrition rate of less than 20%; and (c) 
outcome measures completion rates above 66%. 
  
Methods 
TOPCAT-P is an individually randomised feasibility trial, comparing a personalised, nurse-led, 
psycho-educational intervention with the augmented usual care in North Wales.  
 
Participants 
 Eligible participants (N=305) were identified from hospital records by a team led by the 
Urology Advanced Nurse Practitioner, and were biochemically stable incident prostate cancer 
patients, 9-48 months post-diagnosis, at the end of radical curative treatment (surgery, 
radiotherapy), hormone therapy, or deemed unlikely to receive further treatment (watchful 
waiting). The study excluded men awaiting curative treatment or monitored until proof of 
progression (active surveillance), in the terminal stage of their disease, who lacked capacity, or with 
cognitive, visual or neurological impairments that would impede completing the trial (as assessed by 
the referring clinician). Ninety-five participants were recruited by blinded selection and individually 
randomised to Intervention (N=48) or Control (N=47) groups, on a 1:1 basis and balanced for age 
quartiles (see Stanciu et al., 2015; Appendix A). Participant allocation was revealed to patients and 
researchers after recruitment. 
 
Intervention 
Participants in the Control group continued to receive their usual care delivered outside of 
the trial, and a Macmillan Organiser to self-record and monitor physical and psychological 
symptoms. Patients in the Intervention group received the above, followed by an initial appointment 
with the Research Nurse for a holistic needs assessment, and as many tailored follow-up 
appointments as appropriate (by agreement with the Research Nurse). Further details about the 
training undertaken by the nurse, the rationale and the description of the intervention have already 
been published (Stanciu et al., 2015).  
 
Outcome measures 
 Patient self-reported outcome measures assessed changes in physical symptoms (EPIC-26, 
Expanded Prostate Cancer Index Composite; Szymanski et al., 2010), psychological wellbeing 
(Hospital Anxiety and Depression Scale; Zigmond & Snaith, 1983), confidence in managing own 
health (Lorig at el., 2001), medical and support needs (Supportive Care Needs Survey – simplified 
response format; Boyes, Girgis, & Lecathelinas, 2009; Schofield et al., 2012), and general health and 
quality of life (EuroQoL EQ-5D-5L; Brooks, 1996). The patients’ satisfaction with the healthcare 
services was a secondary outcome measure, and consisted in ratings on a five point Likert scale 
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anchored at “Not at all satisfied” and “Totally satisfied”. This measure was developed and first used 
in the PROSPECTIV trial, and included with the authors’ permission (Watson et al., 2016). The 
Recruiting Officer administered the baseline measures to all patients after consent, and prior to 
randomisation. Subsequent questionnaires were sent by post to be completed by patients in both 
arms and similarly returned to the research team by post (see Table 1). 
 
{Insert Table 1} 
 
 The use of health and social care services during the intervention was measured at 12, 24 
and 36 weeks using a purpose-built Client Service Receipt Inventory (CSRI), documenting the 
frequency and types of contacts with health, social and Third Sector providers. Relevant medical 
history data (e.g., cancer diagnosis, comorbid conditions) were collected from GP records with 
patients’ consent. 
 
Feedback interviews 
 A purposive sample of patients in the Intervention arm (N=25) and GPs whose patients 
received the intervention (N=3) took part in feedback interviews 5-9 months after the end of the 
study. The patient sub-sample was proportionate with the Intervention group for age, cancer stage 
at diagnosis, treatment type, and level of need. GPs were selected among those who had the largest 
number of patients in trial. Interviews wer  semi-structured (see Table 2) and conducted by a 
researcher not involved in the intervention delivery.  
 
{Insert Table 2} 
 
The risk assessment identified a low impact risks for patient safety, with a low probability. 
An independent data monitoring group was not required for this pilot and feasibility study, and 
interim analyses were not conducted. Provisions were made to record all adverse events and serious 
adverse events and to follow them up for the duration of the study or until resolution. Data 
management strategy is reported elsewhere (Stanciu et al., 2015). 
 
Data analysis 
Feasibility metrics were assessed against the predetermined progression criteria. 
Intervention delivery and process evaluation data were analysed descriptively. The preliminary 
analysis of proposed outcome measures followed an intention-to-treat approach and is reported 
descriptively. Limited exploratory inferential analyses are reported in text for secondary outcome 
measures. 
The exploratory health economics analysis adopted a societal perspective due to the 
expected broad impact of the intervention on the NHS (both primary and secondary care), the 
patients, their families, and the third sector. The costing analysis used the national unit costs (Curtis, 
2014).  
The feedback interviews were analysed using a thematic framework approach (Richie & 
Spencer, 1994; Richie, Spencer, & O’Connor, 2003). Two researchers coded the data and identified 
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recurrent themes manually using printed transcripts, in two stages, firstly determining overall 
themes, and secondly, more specific trends and patterns in the data. Difference between coders 
were discussed and settled by agreement. The patients’ and GPs’ interviews were analysed 
separately. 
 
Results 
Feasibility metrics, randomisation, baseline demographic and clinical characteristics 
Between November 2013 and April 2014, 1,469 cases were screened for eligibility, and all 
305 eligible patients were invited to take part in the trial, in two letters sent to them by their 
treating clinician. The reasons for ineligibility are included in Appendix B. Ninety-five patients were 
recruited from January, 2014 to July, 2014, (recruitment rate 31.15%; 95% CI: 25.95% to 36.35%), 
thus, meeting the target of recruiting at least 25% of eligible patients (see Table 3, for baseline 
demographics and clinical characteristics). Five patients declined to participate (1.64%; 95% CI: 
0.21% to 3.07%) and 205 patients did not respond (67.21%; 95% CI: 61.94% to 72.48%).  
The flow of participants through the trial is presented in Figure 1. Three patients withdrew 
from the Intervention group (before their first contact with the Research Nurse) and one patient 
withdrew from the Control group. Five patients were lost to follow-up (Intervention group, N=1; 
Control group N=4). Eighty-six patients completed the trial (retention rate 90.53%; 95% CI: 84.64% to 
96.42%), 44 patients from the Intervention group (retention rate, 91.67%; 95% CI: 83.85% to 
99.49%) and 42 from the Control group (retention rate, 89.36%; 95% CI: 80.54% to 98.18%). Overall 
attrition rate was 9.47% (95% CI: 3.58% to 15.36%), meeting the target of no more than 20% of the 
recruited patients not completing the trial. 
 
{Insert Table 3} 
 
 
{Insert Figure 1} 
 
 
Completion rates of outcome measures were high for all questionnaires: 100% for the 
baseline assessment prior to randomisation for both groups, 92% and 87% (Intervention and Control 
groups respectively) for the follow-up assessment (main outcome measures), 88% and 89% for the 
CSRI (see for details Appendix B). All completed questionnaires were included for analysis. Overall, 
the target completion rate of at least 66% of the recruited participants was achieved for all 
individual measures in each group, both at baseline and follow-up. 
  
Intervention delivery 
The intervention was delivered successfully to all participants (N=45) without significant 
adverse events, over a total of 123 hours of patient contact. Overall, the intervention delivery 
required approximately 10 hours of nurse time per patient (587 minutes), with a larger share of the 
time taken by administrative duties (see Table 4). Half of the patients (N=22) required two 
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appointments to identify and assess all symptoms, and the remaining (N=23) up to four 
appointments (face-to-face or telephone). 
The intervention identified all categories of emotional and physical symptoms predicted in 
the protocol (except for financial concerns), and also new symptoms and concerns, both physical 
and emotional. The most common symptoms were related to physical functioning (urinary 
incontinence, sleep problems, and sexual dysfunction), but the symptoms that took longest to 
address had a significant psychological component (social functioning, living with cancer, and sexual 
dysfunction). Notably, ten patients reported further concerns beyond those identified in the initial 
assessment, later on during the course of the intervention. Most often these were common physical 
symptoms (urinary incontinence, bowel problems, sexual dysfunction) and on few occasions social 
and emotional (social functioning, living with cancer). 
Almost half of the symptoms identified in the intervention had never been reported to a 
healthcare professional before (with reasons included in Appendix C), and the majority of the 
symptoms reported previously to clinicians were physical rather than emotional. Symptoms had 
previously been first reported in secondary care (54%) or to the GP (44%), with attempts to address 
symptoms having had a varied outcome: a third improved or resolved, another third failed to 
improve, but patients reported improved coping, and for the final third both symptoms and patient 
coping remained unchanged. 
 The most frequently used component of the intervention was teaching self-management 
strategies (72%). On fewer occasions, participants received information materials (14%), and were 
signposted (13%) or referred (1%) to other services. The most commonly taught self-management 
strategies were aimed at improving the recognition of symptoms, and the development of coping 
strategies (e.g., symptom self-monitoring, life-style adjustment, cognitive reappraisal). Information 
materials were most often offered in relation to physical symptoms, such as urinary incontinence, 
sexual dysfunction and sleep/fatigue problems. Signposting was most often to the GP (38%), Third 
Sector organisations (29%), or local patient support groups (28%). 
 
{Insert Table 4} 
 
 
Intervention outcome measures 
 Follow-up primary outcome measures data were analysed using ANCOVAs controlling for 
baseline levels (see Appendix D for details). Summary results are reported in Table 5, and informed 
the sample size estimation for a future fully-powered trial. Using EPIC-26 as the primary outcome for 
a future trial would require further consideration of the impact of the intervention on the five 
dimensions of the measure. One approach is to pick the subscale with the largest noted effect (i.e., 
urinary incontinence, d=0.38) as the primary outcome measure. A simple t-test approach to sample 
size, with 90% power and 5% significance would require a total sample of 280 participants. 
Alternatively, all five EPIC-26 subscales could be used, with an adjustment to the significance level 
(α=.01). However, some of the dimensions showed very little change and this will likely inflate the 
sample to an unachievable size. For example, the effect size for hormonal symptoms was 0.1, and 
with a reduced significance level of 1% to accommodate the five dimensions, this approach would 
require a sample of 5954 at 90% power. As it is likely that the analysis in a future trial will 
incorporate the baseline measurements, an ANCOVA would be appropriate, with an estimated 
minimum sample of 88 or 3418 participants, respectively. 
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{Insert Table 5} 
 
 
The participants’ satisfaction with key elements of follow-on cancer care (the intervention’s 
secondary outcome measure) was similar at baseline between the two groups, and seemed to 
improve marginally for the Intervention group at follow-up (Mann-Whitney U tests for emotional 
and psychological symptoms U(57)=252.50, Z=-2.986, p=.03; and relationship problems 
U(46)=172.00, Z=-2.554, p=.011). 
Health economics analysis 
 
 Two sources of data for economic evaluation were used and compared for agreement: a 
bespoke CSRI questionnaires and selected extracts of GP records. Overall, there was a strong 
agreement between respondents’ self-reported data and GP records data, with values ranging from 
66.25% to 90.00% (see Appendix E for details).  
The EQ-5D-5L response rate was 100% at baseline and 88.4% at follow-up. Both participant 
groups reported similar EQ-5D-5L score distributions (median and interquartile range) at baseline 
and follow-up, for each domain (see Appendix E), with a non-significant mean QALY gain of 0.0191 
(bootstrapped 95%CI: -0.0371 to 0.0774) in favour of the Intervention group (see Table 6). 
 In the absence of a significant difference in the primary outcome measures, we performed 
an exploratory cost-consequence analysis (Drummond, Sculpher, Claxton, Stoddart, & Torrance, 
2015). This included the complete data (at baseline and follow-up) of 80 participants (84.2% of the 
clinical sample), and used published national average unit costs for the UK for the year 2013/14 
(Department of Health, 2015). Any costs from previous years were inflated to 2013/14 using the 
Hospital & Community Health Service inflation indices from the national average unit costs.  
 
{Insert Table 6} 
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The mean total cost per participant in the Intervention group was £847 (including the cost of 
delivering the intervention: £354) and £529 for the Control group over the 9 month period between 
baseline and follow-up. Thus the net cost of the intervention was £317 (bootstrapped 95% CI: £46 to 
£558). Further details of the health economic analysis are included in Appendix E. 
 
Feedback interviews with patients and GPs 
The patient interviews revealed four major themes: (1) low research burden; (2) three key 
elements of the intervention; (3) two important aspects of intervention delivery; and (4) a high 
potential for improving the role of the GP and the community care team in prostate cancer follow-up. 
Most patients reported no problems completing the questionnaires at home and returning them at set 
intervals, but some found the CSRI form particularly long. Three most salient aspects of the 
intervention were identified: the psychological support, the practical information about cancer 
survivorship, and the opportunity to speak to the same clinician throughout the intervention. Two 
aspects of the intervention delivery were discussed: timing and location. Firstly, several patients would 
have preferred to receive the intervention sooner in the cancer pathway, when their need was 
greater, but opinions varied on what would be the ideal timeframe. Secondly, many patients preferred 
to have the intervention appointments in a non-clinical environment, pointing to the relaxed 
atmosphere and absence of time pressure as being conducive to exploring their concerns and 
receiving the information and psychological support needed. Finally, patients perceived the GP’s role 
in their follow-up care to be presently very limited. This contrasted the patients’ high confidence in the 
Research Nurse, and preference to receive this support generally out of the hospital, in the 
community. 
 The interviewed GPs recognised the importance of the extra nurse support delivered in the 
intervention. One GP mentioned the positive effect it had on the patients seen in clinic, without any 
noticeable impact on own workload, and another GP estimated that the intervention may have 
reduced the number of times patients came to seek an appointment. However, all GPs identified 
substantial capacity challenges to integrating a similar type of support in the services provided by their 
practice (e.g., staff recruitment, funding the posts, and available clinical space; see Appendix F for 
details). 
 
Discussion 
 All feasibility and acceptability targets were achieved during the study. Feedback 
questionnaires with patients and GPs revealed a high level of support for the intervention, and 
identified opportunities for a future effectiveness evaluation. The intervention was delivered 
successfully without significant adverse events. Potential intervention outcome measures have been 
successfully tested and minimum sample size of 230 participants was estimated to be needed for a 
fully-power trial with EPIC-26 as the primary outcome measure. For the economic evaluation of the 
intervention, alternatives to the EQ-5D-5L should be considered, for example, the Short Form 36 
Health Survey Questionnaire (SF-36; Brazier et al., 1992), Health Utility Index (HUI; Horsman, Furlong, 
Feeny, & Torrance, 2003), or the ICEpop CAPability measure for adults (ICECAP-A; Al-Janabi, Flynn, & 
Coast, 2012).  
 
Implication for a future delivery of the intervention 
Three major elements of care provided by the intervention should inform future practice. 
Importantly, the intervention nearly doubled the number of cancer survivorship symptoms ever 
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reported by participants, and the underreporting of symptoms by cancer survivors is well-known 
(Breetvelt & Van Dam, 1991; Ristvedt & Trinkaus, 2005). The range of reasons why patients failed to 
report the symptoms previously was varied, but two critical elements seemed to be a structured 
consultation (i.e., “clinician had not asked”), and sufficient time. Moreover, a quarter of patients 
continued to reveal symptoms, beyond those initially reported in the comprehensive self-screening 
instrument used in the trial. Notably, these were common, high burden symptoms, which were 
arguably top-of-mind for patients, such as urinary incontinence, sexual dysfunction, and bowel 
problems. Thus, the reasons for the initial under-reporting may be psychological. The rapport and 
continuity of care provided by the research nurse may have facilitated their subsequent reporting. It 
was beyond the aim of the present study to establish why patient underreport obvious and significant 
prostate cancer sequelae. However, alongside a structured consultation and sufficient time 
(mentioned by patients during the intervention), continuity of care seems to be a third essential 
component of follow-up care (as identified by patients in the feedback interviews). 
 Risk stratification is often employed to identify patients with “highest need” and selectively 
target interventions to improve their effectiveness (Watson et al., 2012). However, this was not 
supported by the present data. Firstly, as discussed earlier, almost half of the symptoms assessed and 
managed in the intervention had not been reported before, thus, restricting the patients’ access to the 
intervention would result in many patients and their unmet needs being missed. Secondly, the 
sensitivity of screening instruments is inherently limited. This was highlighted presently when patients 
failed to identify common and high-burden symptoms initially, but did so eventually throughout the 
trial. Therefore, a stratification of needs prior to the exploration of symptoms and concerns is likely to 
miss a significant number of patients and unmet needs, many of which might have never been 
reported before. 
 The effectiveness of the intervention could potentially be increased by improving the timing of 
its delivery. There was no single time point preferred by all the patients, but the data suggested that 
possibly many would benefit from having the extra psychological support and information available 
earlier in the cancer pathway, soon after diagnosis and before the treatment decision. This would 
allow patients to access the support, as needed, at any point (1) after diagnosis, and before deciding 
on the treatment option, (2) after the end the of the treatment, and (3) for some patients even some 
time after the end of the treatment. The difference from current usual practice is that the holistic 
needs assessment would need to be made available at an earlier stage (after diagnosis), and followed-
up with psychological support and information if-and-when needed. As the patient progresses through 
the cancer pathway, the holistic needs assessment could be updated (e.g., at the end of the 
treatment, or later in the recovery period, by agreement between patient and clinician). As shown in 
the present feasibility trial, giving patients the opportunity to complete a holistic needs assessment 
raises their awareness of possible psychological and physical concerns. This, in turn, makes it more 
likely for patients to report symptoms earlier and seek adequate management or coping strategies. 
Beginning this assessment and management process early is likely to produce a greater improvement 
in the patients’ quality of life than an intervention delivered once patients are ready for discharge 
from secondary care. 
 
Methodological implications for future research 
 The administrative burden in this trial was high, but can be improved in a future fully-powered 
trial, by using simpler, electronic case report forms, which can be completed immediately after the 
appointment (e.g., on a tablet or portable computer). The nurse planning time was approximately one 
quarter of the patient contact time, and was used by the nurse to review the patient documentation, 
plan the upcoming appointment, and prepare the information materials related to the symptoms and 
relevant self-management techniques. This process too could be optimised further, as the range and 
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frequency of the information materials needed can be estimated from the extensive results of the 
current trial. 
 
Conclusions 
 TOPCAT-P confirmed that the level of need of prostate cancer survivors is varied, and in many 
cases, substantial, having a considerable impact on quality of life. The successful feasibility trial 
suggested incremental improvements to the intervention and usual care. However, the fundamental 
questions regarding the effectiveness and cost-effectiveness of these changes remain to be answered 
by a future fully-powered trial. 
 
  
Page 10 of 27
European Journal of Cancer Care
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
TOPCAT-P; RCT of nurse-led intervention 
11 
 
References 
Al-Janabi, H., Flynn, T. N., & Coast, J. (2012). Development of a self-report measure of capability 
wellbeing for adults: the ICECAP-A. Quality of Life Research, 21(1), 167-176.  doi: 
https://doi.org/10.1007/s11136-011-9927-2 
Armes, J., Crowe, M., Colbourne, L., Morgan, H., Murrells, T., Oakley, C., ... & Richardson, A. (2009). 
Patients' supportive care needs beyond the end of cancer treatment: a prospective, 
longitudinal survey. Journal of Clinical Oncology, 27(36), 6172-6179. doi: 
10.1200/JCO.2009.22.5151 
Boyes, A., Girgis, A., & Lecathelinais, C. (2009). Brief assessment of adult cancer patients' perceived 
needs: development and validation of the 34-item Supportive Care Needs Survey (SCNS-SF34). 
Journal of evaluation in clinical practice, 15(4), 602-606.doi:10.1111/j.1365-2753.2008.01057.x 
Brazier, J. E., Harper, R., Jones, N. M., O'cathain, A., Thomas, K. J., Usherwood, T., & Westlake, L. 
(1992). Validating the SF-36 health survey questionnaire: new outcome measure for primary 
care. BMJ, 305(6846), 160-164.  doi: https://doi.org/10.1136/bmj.305.6846.160  
Breetvelt, I.S., & Van Dam, F.S.A.M. (1991). Underreporting by cancer patients: the case of response-
shift. Social science & medicine, 32(9), 981-987. doi: https://doi.org/10.1016/0277-
9536(91)90156-7 
Brooks R. (1996). EuroQol: the current state of play. Health Policy, 37(1):53-72 doi:10.1016/0168-
8510(96)00822-6. 
Bulger, J. K., Hiscock, J., Neal, R. D., Stanciu, A., Makin, M., & Wilkinson, C. (2015). ‘Carrying on the way 
we are is becoming shambolic’–An interview study with prostate cancer specialists about their 
usual practice of follow-up. Journal of Clinical Urology, 8(4), 240-245. DOI: 
10.1177/2051415814545804 
Cockle-Hearne, J., Charnay-Sonnek, F., Denis, L., Fairbanks, H. E., Kelly, D., Kav, S., ... & Faithfull, S. 
(2013). The impact of supportive nursing care on the needs of men with prostate cancer: a 
study across seven European countries. British journal of cancer, 109(8), 2121-2130. 
doi:10.1038/bjc.2013.568 
Craig, P., Dieppe, P., Macintyre, S., Michie, S., Nazareth, I., & Petticrew, M. (2013). Developing and 
evaluating complex interventions: the new Medical Research Council guidance. International 
journal of nursing studies, 50(5), 587-592. doi:10.1016/j.ijnurstu.2012.09.010. 
Crawford, E. D., Grubb III, R., Black, A., Andriole Jr, G. L., Chen, M.H., Izmirlian, G., ... & D'Amico, A. V. 
(2010). Comorbidity and mortality results from a randomized prostate cancer screening trial. 
Journal of Clinical Oncology, 29(4), 355-361. doi:10.1200/JCO.2010.30.5979  
Curtis L. (2014). Unit costs of health and social care 2014. Kent: Personal Social Services Research Unit 
2014. http://www.pssru.ac.uk/project-pages/unit-costs/2014/ (accessed on 2 March 2015). 
Daskivich, T.J., Fan, K. H., Koyama, T., Albertsen, P. C., Goodman, M., Hamilton, A. S., ... & Penson, D. F. 
(2013). Effect of age, tumor risk, and comorbidity on competing risks for survival in a US 
population–based cohort of men with prostate cancer. Annals of internal medicine, 158(10), 
709-717. doi: 10.7326/0003-4819-158-10-201305210-00005. 
Department of Health. (2015). NHS Cost reference costs 2013-2014. Available from: 
https://www.gov.uk/government/publications/nhs-reference-costs-2013-to-2014 [Accessed 
on: 2nd October 2015] 
Page 11 of 27
European Journal of Cancer Care
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
TOPCAT-P; RCT of nurse-led intervention 
12 
 
Drummond, M., Sculpher, M.J., Claxton, K., Stoddart, G.L., & Torrance, G.W. (2015). Methods for the 
Economic Evaluation of Health Care Programmes 4th edition. Oxford University Press: Oxford. 
Gilbody, S. (2004). Review: disease management programmes improve detection and care of people 
with depression. Evidence Based Mental Health, 7(3):80 doi:10.1136/ebmh.7.3.80. 
Harden, J., Sanda, M. G., Wei, J. T., Yarandi, H. N., Hembroff, L., Hardy, J., & Northouse, L. (2013, 
November). Survivorship after prostate cancer treatment: spouses’ quality of life at 36 
months. In Oncology nursing forum, 40(6), 567. NIH Public Access. doi: 10.1188/13.ONF.567-
573. 
Horsman, J., Furlong, W., Feeny, D., & Torrance, G. (2003). The Health Utilities Index (HUI®): concepts, 
measurement properties and applications. Health and quality of life outcomes, 1(1), 54. 
doi:https://doi.org/10.1186/1477-7525-1-54 
Jefford, M., Aranda, S., Gough, K., Lotfi-Jam, K., Butow, P., Krishnasamy, M., ... & Schofield, P. (2013). 
Evaluating a nurse-led survivorship care package (SurvivorCare) for bowel cancer survivors: 
study protocol for a randomized controlled trial. Trials, 14(1), 260. doi:10.1186/1745-6215-14-
260. 
Lewis, R., Neal, R. D., Williams, N. H., France, B., Wilkinson, C., Hendry, M., ... & Weller, D. (2009). 
Nurse-led vs. conventional physician-led follow-up for patients with cancer: systematic review. 
Journal of advanced nursing, 65(4), 706-723. doi: 10.1111/j.1365-2648.2008.04927.x  
Lorig, K. R., Sobel, D. S., Ritter, P. L., Laurent, D., & Hobbs, M. (2001). Effect of a self-management 
program on patients with chronic disease. Effective clinical practice: ECP, 4(6), 256-262.. 
NMC - Nursing and Midwifery Council. Standards for competence for registered nurses. (2015). 
https://www.nmc.org.uk/globalassets/sitedocuments/standards/nmc-standards-for-
competence-for-registered-nurses.pdf [Accessed on: 28 June 2017) 
Northouse, L. L., Mood, D. W., Montie, J. E., Sandler, H. M., Forman, J. D., Hussain, M., ... & Kershaw, T. 
(2007). Living with prostate cancer: patients' and spouses' psychosocial status and quality of 
life. Journal of Clinical Oncology, 25(27), 4171-4177. doi:10.1200/JCO.2006.09.65003  
Ream, E., Quennell, A., Fincham, L., Faithfull, S., Khoo, V., Wilson-Barnett, J., & Richardson, A. (2008). 
Supportive care needs of men living with prostate cancer in England: a survey. British Journal 
of Cancer, 98(12), 1903-1909. doi:10.1038/sj.bjc.6604406  
Renders, C. M., Valk, G. D., Griffin, S. J., Wagner, E., van Eijk, J. T., & Assendelft, W. J. (2000). 
Interventions to improve the management of diabetes mellitus in primary care, outpatient and 
community settings. The Cochrane Library. 1:CD001481 doi: 10.1002/14651858.CD001481 
Richardson, A., Griffin, M., Miller, C., & McNeil, I. (2008). Living life after cancer treatment: a nurse-led 
support service. Cancer Nursing Practice, 7(10), 36-38. doi:10.7748/cnp2008.12.7.10.36.c7553. 
Ristvedt, S. L., & Trinkaus, K. M. (2005). Psychological factors related to delay in consultation for 
cancer symptoms. Psycho-Oncology, 14(5), 339-350. doi: 10.1002/pon.850 
Ritchie J, Spencer L, O’Connor W. (2003). Carrying out qualitative analysis. In J. Lewis & J. Ritchie (Eds.), 
Qualitative research practice, Sage:London, UK. 
Ritchie, J., & Spencer, L. (1994). Analysing Qualitative Data. Routledge: London (UK). 
Russell, D., Hoare, Z. S. J., Whitaker, R. H., Whitaker, C. J., & Russell, I. T. (2011). Generalized method 
for adaptive randomization in clinical trials. Statistics in Medicine, 30(9), 922-934.. doi: 
10.1002/sim.4175. 
Page 12 of 27
European Journal of Cancer Care
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
TOPCAT-P; RCT of nurse-led intervention 
13 
 
Schofield, P., Gough, K., Lotfi-Jam, K., & Aranda, S. (2012). Validation of the Supportive Care Needs 
Survey—short form 34 with a simplified response format in men with prostate cancer. Psycho-
Oncology, 21(10), 1107-1112. doi: 10.1002/pon.2016  
Segrin, C., Badger, T. A., & Harrington, J. (2012). Interdependent psychological quality of life in dyads 
adjusting to prostate cancer. Health Psychology, 31(1), 70. doi:10.1037/a0025394 
Shahinian, V. B., Kuo, Y. F., Freeman, J. L., & Goodwin, J. S. (2005). Risk of fracture after androgen 
deprivation for prostate cancer. New England Journal of Medicine, 352(2), 154-164. 
doi:10.1056/NEJMoa041943. 
Skolarus, T. A., Wittmann, D., Northouse, L., An, L. C., Olson, K. B., Rew, K. T., ... & Holmes-Rovner, M. 
(2014). Recommendations for prostate cancer survivorship care: an update to the 2009 
Michigan cancer consortium guidelines for the primary care management of prostate cancer 
post-treatment sequelae. Journal of Men's Health, 11(3), 95-107. 
doi:10.1089/jomh.2014.0026. 
Smith, D. P., King, M. T., Egger, S., Berry, M. P., Stricker, P. D., Cozzi, P., ... & Armstrong, B. K. (2009). 
Quality of life three years after diagnosis of localised prostate cancer: population based cohort 
study. BMJ, 339, b4817. doi:10.1135/bmjb4817. 
Smittenaar, C. R., Petersen, K. A., Stewart, K., & Moitt, N. (2016). Cancer incidence and mortality 
projections in the UK until 2035. British journal of cancer, 115(9), 1147-
1155.doi:10.1038/bjc.2016.304. 
Stanciu, M. A., Morris, C., Makin, M., Watson, E., Bulger, J., Evans, R., ... & Wilkinson, C. (2015). A pilot 
randomised controlled trial of personalised care after treatment for prostate cancer (TOPCAT-
P): nurse-led holistic-needs assessment and individualised psychoeducational intervention: 
study protocol. BMJ open, 5(6), e008470. doi:10.1136/bmjopen-2015-008470 
Stein, K.D., Syrjala, K.L., & Andrykowski, M.A. (2008). Physical and psychological long-term and late 
effects of cancer. Cancer, 112(S11), 2577-2592. doi: 10.1002/cncr.23448 
Szymanski, K. M., Wei, J. T., Dunn, R. L., & Sanda, M. G. (2010). Development and validation of an 
abbreviated version of the expanded prostate cancer index composite instrument for 
measuring health-related quality of life among prostate cancer survivors. Urology, 76(5), 1245-
1250. doi:10.1016/j.urology.2010.01.027. 
Watson, E., Shinkins, B., Frith, E., Neal, D., Hamdy, F., Walter, F., ... & Sooriakumaran, P. (2016). 
Symptoms, unmet needs, psychological well-being and health status in survivors of prostate 
cancer: implications for redesigning follow-up. BJU international, 117(6B). 
doi:10.1111/bju.13122. 
Watson, M. & Kissane, D.W. (2011). Handbook of psychotherapy in cancer care. Wiley-Blackwell 
Chichester, UK. 
Watson, E. K., Rose, P. W., Neal, R. D., Hulbert-Williams, N., Donnelly, P., Hubbard, G., ... & Wilkinson, 
C. (2012). Personalised cancer follow-up: risk stratification, needs assessment or both?. British 
Journal of Cancer, 106(1), doi:  10.1038/bjc.2011.535 
Zigmond, A.S. & Snaith, R.P. (1983). The hospital anxiety and depression scale. Acta Psychiatrica 
Scandinavica, 67:361–70. 
 
  
Page 13 of 27
European Journal of Cancer Care
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
TOPCAT-P; RCT of nurse-led intervention 
14 
 
Table 1. Timeline of intervention delivery and outcome measures 
 Augmented Usual Care Nurse-led Intervention 
T0 T1 T2 T3 T0 T1 T2 T3 
Consent 12 weeks 24 weeks 36 weeks Consent 12 weeks 24 weeks 36 weeks 
Follow-up 
care 
Macmillan organiser         
Routine signposting to Macmillan 
information centre, GP, hospital services 
        
Ongoing follow-up appointments    
Holistic need assessment      
Follow-up appointments      
Outcome 
measures 
EPIC-26, HADS, SCNS-34, EQ-5D-5L, 
confidence in managing own health, 
satisfaction with health care services 
        
Client Service Receipt Inventory         
Feedback interview         
Note: GP: General Practitioner; EPIC-26: The Expanded Prostate Cancer Index Composite – Short Form (26 items); HADS: Hospital Anxiety and Depression 
Scale; SCNS-34: Supportive Care Needs Survey - Short Form (34 items); EQ-5D-5L: The 5-level EQ-5D version. 
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Table 2. Feedback interview schedule for patients and GPs 
The main topics of the interview schedule for patients: 
1) experience of the intervention (perceived benefits, missed opportunities, 
and possible broader impact) 
2) information received about prostate cancer survivorship 
3) views on the routine usual care received from the National Health 
Service  
4) feedback on improving the intervention (timing, location, and delivery)  
5) feedback on completing the research trial (communication with research 
staff, outcome measures completion, other aspects of participant burden) 
 
The main topics of the interview schedule for GPs: 
1) the impact of the intervention on patients seen in general practice 
2) the impact of the intervention on GPs’ own work 
3) the communication with the research nurse (including the patients’ 
holistic needs assessment and personalised care plan) 
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Table 3. Baseline demographic and clinical characteristics for the Intervention and Control groups. 
 Intervention 
group (N) 
Control 
group (N) 
Total 
(N) 
Age group (balancing variable) 48 47 95 
48-65 9 7 16 
66-72 17 19 36 
73-80 18 18 36 
81-94 4 3 7 
Ethnicity 48 47 95 
White British 48 47 95 
Marital status 48 47 95 
Married or living as married 34 42 76 
Widowed 7 3 10 
In partnership, but not cohabiting 2 1 3 
Divorced or separated 2 1 3 
Single 3 - 3 
Employment 48 47 95 
Retired from paid work 41 37 78 
In paid work (including self-employment) - full or part time 6 8 14 
Unable to work because of long-term disability or ill health - 2 2 
Temporarily off sick from my job 1 - 1 
Highest qualification 48 47 95 
College or university degree, HND or HNC 12 13 25 
O' Level, GCSE or equivalent 9 11 20 
A' level or equivalent 3 6 9 
Postgraduate qualification 4 3 7 
Clerical or commercial qualification 3 2 5 
Other 17 12 29 
Treatment type 48 47 95 
Radiotherapy 19 24 43 
Surgery 18 16 34 
Hormone therapy 8 5 13 
Watchful waiting 3 2 5 
Chronic comorbid conditions 48 47 95 
High blood pressure (hypertension) 20 20 40 
Rheumatoid or osteoarthritis 12 10 22 
Heart problems 8 8 16 
Asthma 6 3 9 
Diabetes 4 3 7 
Chronic Obstructive Pulmonary Disease (COPD) 3 2 5 
Osteoporosis 2 2 4 
Ischaemic heart disease (IHD) 2 1 3 
Inflammatory Bowel Disease (e.g., Crohn's disease, colitis) 1 1 2 
Upper Gastrointestinal Tract disease (Upper GIT) 2 - 2 
Chronic kidney disease (CKD) 1 1 2 
Stroke - 1 1 
Note: HND = Higher National Diploma; HNC = Higher National Certificate 
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Table 4. The duration of the intervention (in minutes), and the distance travelled (in miles) per patients and per appointment. 
 
Total 
Intervention duration/distance travelled 
per patient 
Intervention duration/distance travelled 
per appointment 
N Mean SD N Mean SD 
Intervention duration (minutes) (patients) (minutes)  (minutes) (appointments)   (minutes) (minutes)  
Nurse Planning Time 1,743 45 39 19 121 14 5 
Nurse Travel Time 959 17 56 39 33 29 13 
Nurse Contact Time 7,385 45 164 121 121 61 34 
Nurse Admin Time 14,752 45 328 259 121 122 76 
Patient Travel Time 1,125 45 25 24 95 25 11 
Travel Distance (miles) (patients) (miles) (miles) (appointments) (miles) (miles) 
Nurse Travel Distance 676 17 40 34 33 20 17 
Patient Travel Distance 377 45 8 8 95 4 3 
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Table 5. Comparison between the Intervention and Control groups at follow-up, for all five 
intervention outcome measures (N=follow-up sample size; EMM=estimated marginal means 
(adjusted for baseline levels) with 95% confidence intervals; SE=standard error).  
 Intervention group Control group 
N EMM (95%CI) SE N EMM (95%CI) SE 
Expanded Prostate Cancer Index Composite (EPIC-26) 
Urinary Incontinence 34 75.8 (71.5-80.1) 2.2 37 81.7 (77.5-85.8) 2.1 
Urinary irritative / obstructive 34 86.8 (83.2-90.5) 1.8 37 88.9 (85.4-92.4 1.8 
Bowel symptoms 40 91.2 (87.5-94.9) 1.9 38 91.6 (87.8-95.5) 1.9 
Sexual symptoms 41 21.4 (17.1-25.7) 2.2 40 21.7 (17.4-26.1) 2.2 
Hormonal symptoms 39 81.2 (75.9-86.5) 2.7 39 84.7 (75.9-86.5) 2.7 
Self-confidence in managing own health 
Overall Score (average) 42 8.5 (8.2-8.9) 0.2 39 8.3 (7.9-8.7) 0.2 
Supportive Care Needs Survey (SCNS-SF34) summed scores 
Psychological 43 17.2 (15.5-18.9) 0.9 40 17.1 (15.4-18.9) 0.9 
Health Systems and Information 42 17.6 (14.9-20.3) 1.4 40 17.0 (14.2-19.7) 1.4 
Physical and daily living 42 7.8 (6.8-8.7) 0.5 40 7.8 (6.8-8.8) 0.5 
Patient care and support 43 7.3 (6.2-8.4) 0.6 40 7.0 (5.8-8.1) 0.6 
Sexuality 42 5.5 (4.7-6.3) 0.4 39 5.6 (4.8-6.4) 0.4 
Hospital Anxiety and Depression Scale (HADS) 
Anxiety 42 3.9 (3.2-4.6) 0.4 41 3.5 (2.8-4.2) 0.3 
Depression 42 3.6 (2.9-4.2) 0.3 41 3.8 (3.2-4.4) 0.3 
EuroQol 5D-5L quality of life index 
Index score (%) 42 76.1 (71.7-80.5) 2.2 40 78.7 (74.3-83.2) 2.2 
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Table 6. Self-reported EQ-5D-5L index scores, mean QALYs and incremental mean QALYs at 9 months follow-up by group (N= 80). 
1
 Incremental mean QALYs between groups=mean QALYs for Intervention group minus mean QALYs for control group 
 
 Intervention (N= 40) 
Mean (SD) 
Control (N= 40) 
Mean (SD) 
 Incremental mean QALYs 
between groups
1
 
(bootstrapped 95% CI) Measure Baseline 9 months 
QALY 
over 9 months 
Baseline 9 months 
QALY 
over 9 months 
EQ-5D-5L index 
0.8257 
(0.1436) 
0.8184 
(0.1895) 
0.6165 
(0.1194) 
0.7942 
(0.1935) 
0.7989 
(0.1937) 
0.5974 
(0.1397) 
0.0191 
(-0.0371 to 0.0774) 
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Figure 1. CONSORT diagram showing the flow of participants through each phase of the TOPCAT-P 
trial. 
 
Assessed for eligibility (N=1,469) 
Randomised (N=95) 
Allocated to nurse-led 
intervention and augmented usual 
care (Intervention group) (N=48) 
 
     Received allocated intervention 
(N=45) 
     Did not receive allocated 
intervention (withdrawal pre-
intervention: carer burden, family 
loss) (N=3) 
Allocated to augmented usual 
care (Control group) (N=47) 
 
 
     Received allocated intervention 
(N=46) 
     Did not receive allocated 
intervention (withdrawal due to 
change in personal circumstances) 
(N=1) 
Lost to follow-up (did not 
respond) (N=1) 
Lost to follow-up (did not 
respond) (N=4) 
Analysed (N=45) 
Excluded (N=1,374) 
Not meeting inclusion criteria 
(N=1,164) 
Declined to participate (N=5) 
Did not respond (N=205) 
Included (N=305) 
Analysed (N=46) 
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Table 1. Timeline of intervention delivery and outcome measures 
 Augmented Usual Care Nurse-led Intervention 
T0 T1 T2 T3 T0 T1 T2 T3 
Consent 12 weeks 24 weeks 36 weeks Consent 12 weeks 24 weeks 36 weeks 
Follow-up 
care 
Macmillan organiser         
Routine signposting to Macmillan 
information centre, GP, hospital services 
        
Ongoing follow-up appointments    
Holistic need assessment      
Follow-up appointments      
Outcome 
measures 
EPIC-26, HADS, SCNS-34, EQ-5D-5L, 
confidence in managing own health, 
satisfaction with health care services 
        
Client Service Receipt Inventory         
Feedback interview         
Note: GP: General Practitioner; EPIC-26: The Expanded Prostate Cancer Index Composite – Short Form (26 items); HADS: Hospital Anxiety and Depression 
Scale; SCNS-34: Supportive Care Needs Survey - Short Form (34 items); EQ-5D-5L: The 5-level EQ-5D version. 
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1 
 
Table 2. Feedback interview schedule for patients and GPs 
The main topics of the interview schedule for patients: 
1) experience of the intervention (perceived benefits, missed opportunities, 
and possible broader impact) 
2) information received about prostate cancer survivorship 
3) views on the routine usual care received from the National Health 
Service  
4) feedback on improving the intervention (timing, location, and delivery)  
5) feedback on completing the research trial (communication with research 
staff, outcome measures completion, other aspects of participant burden) 
 
The main topics of the interview schedule for GPs: 
1) the impact of the intervention on patients seen in general practice 
2) the impact of the intervention on GPs’ own work 
3) the communication with the research nurse (including the patients’ 
holistic needs assessment and personalised care plan) 
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Table 3. Baseline demographic and clinical characteristics for the Intervention and Control groups. 
 Intervention 
group (N) 
Control 
group (N) 
Total 
(N) 
Age group (balancing variable) 48 47 95 
48-65 9 7 16 
66-72 17 19 36 
73-80 18 18 36 
81-94 4 3 7 
Ethnicity 48 47 95 
White British 48 47 95 
Marital status 48 47 95 
Married or living as married 34 42 76 
Widowed 7 3 10 
In partnership, but not cohabiting 2 1 3 
Divorced or separated 2 1 3 
Single 3 - 3 
Employment 48 47 95 
Retired from paid work 41 37 78 
In paid work (including self-employment) - full or part time 6 8 14 
Unable to work because of long-term disability or ill health - 2 2 
Temporarily off sick from my job 1 - 1 
Highest qualification 48 47 95 
College or university degree, HND or HNC 12 13 25 
O' Level, GCSE or equivalent 9 11 20 
A' level or equivalent 3 6 9 
Postgraduate qualification 4 3 7 
Clerical or commercial qualification 3 2 5 
Other 17 12 29 
Treatment type 48 47 95 
Radiotherapy 19 24 43 
Surgery 18 16 34 
Hormone therapy 8 5 13 
Watchful waiting 3 2 5 
Chronic comorbid conditions 48 47 95 
High blood pressure (hypertension) 20 20 40 
Rheumatoid or osteoarthritis 12 10 22 
Heart problems 8 8 16 
Asthma 6 3 9 
Diabetes 4 3 7 
Chronic Obstructive Pulmonary Disease (COPD) 3 2 5 
Osteoporosis 2 2 4 
Ischaemic heart disease (IHD) 2 1 3 
Inflammatory Bowel Disease (e.g., Crohn's disease, colitis) 1 1 2 
Upper Gastrointestinal Tract disease (Upper GIT) 2 - 2 
Chronic kidney disease (CKD) 1 1 2 
Stroke - 1 1 
Note: HND = Higher National Diploma; HNC = Higher National Certificate 
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Table 4. The duration of the intervention (in minutes), and the distance travelled (in miles) per patients and per appointment. 
 
Total 
Intervention duration/distance travelled 
per patient 
Intervention duration/distance travelled 
per appointment 
N Mean SD N Mean SD 
Intervention duration (minutes) (patients) (minutes)  (minutes) (appointments)   (minutes) (minutes)  
Nurse Planning Time 1,743 45 39 19 121 14 5 
Nurse Travel Time 959 17 56 39 33 29 13 
Nurse Contact Time 7,385 45 164 121 121 61 34 
Nurse Admin Time 14,752 45 328 259 121 122 76 
Patient Travel Time 1,125 45 25 24 95 25 11 
Travel Distance (miles) (patients) (miles) (miles) (appointments) (miles) (miles) 
Nurse Travel Distance 676 17 40 34 33 20 17 
Patient Travel Distance 377 45 8 8 95 4 3 
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Table 5. Comparison between the Intervention and Control groups at follow-up, for all five 
intervention outcome measures (N=follow-up sample size; EMM=estimated marginal means 
(adjusted for baseline levels) with 95% confidence intervals; SE=standard error).  
 Intervention group Control group 
N EMM (95%CI) SE N EMM (95%CI) SE 
Expanded Prostate Cancer Index Composite (EPIC-26) 
Urinary Incontinence 34 75.8 (71.5-80.1) 2.2 37 81.7 (77.5-85.8) 2.1 
Urinary irritative / obstructive 34 86.8 (83.2-90.5) 1.8 37 88.9 (85.4-92.4 1.8 
Bowel symptoms 40 91.2 (87.5-94.9) 1.9 38 91.6 (87.8-95.5) 1.9 
Sexual symptoms 41 21.4 (17.1-25.7) 2.2 40 21.7 (17.4-26.1) 2.2 
Hormonal symptoms 39 81.2 (75.9-86.5) 2.7 39 84.7 (75.9-86.5) 2.7 
Self-confidence in managing own health 
Overall Score (average) 42 8.5 (8.2-8.9) 0.2 39 8.3 (7.9-8.7) 0.2 
Supportive Care Needs Survey (SCNS-SF34) summed scores 
Psychological 43 17.2 (15.5-18.9) 0.9 40 17.1 (15.4-18.9) 0.9 
Health Systems and Information 42 17.6 (14.9-20.3) 1.4 40 17.0 (14.2-19.7) 1.4 
Physical and daily living 42 7.8 (6.8-8.7) 0.5 40 7.8 (6.8-8.8) 0.5 
Patient care and support 43 7.3 (6.2-8.4) 0.6 40 7.0 (5.8-8.1) 0.6 
Sexuality 42 5.5 (4.7-6.3) 0.4 39 5.6 (4.8-6.4) 0.4 
Hospital Anxiety and Depression Scale (HADS) 
Anxiety 42 3.9 (3.2-4.6) 0.4 41 3.5 (2.8-4.2) 0.3 
Depression 42 3.6 (2.9-4.2) 0.3 41 3.8 (3.2-4.4) 0.3 
EuroQol 5D-5L quality of life index 
Index score (%) 42 76.1 (71.7-80.5) 2.2 40 78.7 (74.3-83.2) 2.2 
 
 
Page 25 of 27
European Journal of Cancer Care
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Table 6. Self-reported EQ-5D-5L index scores, mean QALYs and incremental mean QALYs at 9 months follow-up by group (N= 80). 
1
 Incremental mean QALYs between groups=mean QALYs for Intervention group minus mean QALYs for control group 
 
 Intervention (N= 40) 
Mean (SD) 
Control (N= 40) 
Mean (SD) 
 Incremental mean QALYs 
between groups
1
 
(bootstrapped 95% CI) Measure Baseline 9 months 
QALY 
over 9 months 
Baseline 9 months 
QALY 
over 9 months 
EQ-5D-5L index 
0.8257 
(0.1436) 
0.8184 
(0.1895) 
0.6165 
(0.1194) 
0.7942 
(0.1935) 
0.7989 
(0.1937) 
0.5974 
(0.1397) 
0.0191 
(-0.0371 to 0.0774) 
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Figure 1. CONSORT diagram showing the flow of participants through each phase of the TOPCAT-P 
trial. 
 
Assessed for eligibility (N=1,469) 
Randomised (N=95) 
Allocated to nurse-led 
intervention and augmented usual 
care (Intervention group) (N=48) 
 
     Received allocated intervention 
(N=45) 
     Did not receive allocated 
intervention (withdrawal pre-
intervention: carer burden, family 
loss) (N=3) 
Allocated to augmented usual 
care (Control group) (N=47) 
 
 
     Received allocated intervention 
(N=46) 
     Did not receive allocated 
intervention (withdrawal due to 
change in personal circumstances) 
(N=1) 
Lost to follow-up (did not 
respond) (N=1) 
Lost to follow-up (did not 
respond) (N=4) 
Analysed (N=45) 
Excluded (N=1,374) 
Not meeting inclusion criteria 
(N=1,164) 
Declined to participate (N=5) 
Did not respond (N=205) 
Included (N=305) 
Analysed (N=46) 
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